A Phase I, Open-label, Dose Escalation Study of Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer
Phase of Trial: Phase I
Latest Information Update: 04 Oct 2016
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 26 Sep 2016 Planned End Date changed from 1 May 2017 to 1 Jul 2018.
- 26 Sep 2016 Planned primary completion date changed from 1 May 2016 to 1 Jul 2017.